Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Evofem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Kyowa Pharmaceutical Industry","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"TAIWAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2021","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bora Pharmaceuticals Partners with TaiRx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bora Pharmaceuticals Completes Acquisition of Upsher-Smith","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Bora Pharmaceuticals

    Menu

    Bora Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Bora Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual BoothBora Pharmaceuticals- Making success more certain.
              Contact Supplier Contact Supplier
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bora Pharmaceuticals Completes Acquisition of Upsher-Smith

              Details:

              Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.

              Lead Product(s): Amantadine Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: Amantadine HCl-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Upsher-Smith Laboratories

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition April 01, 2024

              Bora Pharmaceutical

              Bio Korea

              Booth #A4

              envelop Contact Supplier

              Bora Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual BoothBora Pharmaceuticals- Making success more certain.
              Contact Supplier Contact Supplier
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M

              Details:

              Through the acquisition, Bora gains Upsher-Smith’s product portfolio, including Amantadine hydrochloride, indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.

              Lead Product(s): Amantadine Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: Amantadine HCl-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Upsher-Smith Laboratories

              Deal Size: $210.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition January 18, 2024

              Bora Pharmaceutical

              Bio Korea

              Booth #A4

              envelop Contact Supplier

              Bora Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual BoothBora Pharmaceuticals- Making success more certain.
              Contact Supplier Contact Supplier
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC

              Details:

              Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.

              Lead Product(s): CT-G20

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: CT-G20

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Celltrion

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership April 06, 2023

              Bora Pharmaceutical

              Bio Korea

              Booth #A4

              envelop Contact Supplier

              Bora Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual BoothBora Pharmaceuticals- Making success more certain.
              Contact Supplier Contact Supplier
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bora Pharmaceuticals Partners with TaiRx

              Details:

              CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors.

              Lead Product(s): Foslinanib,Sorafenib

              Therapeutic Area: Oncology Product Name: CVM-1118

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: TaiRx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 27, 2022

              Bora Pharmaceutical

              Bio Korea

              Booth #A4

              envelop Contact Supplier

              Bora Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual BoothBora Pharmaceuticals- Making success more certain.
              Contact Supplier Contact Supplier
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®

              Details:

              Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.

              Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Phexxi

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Evofem Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 10, 2022

              Bora Pharmaceutical

              Bio Korea

              Booth #A4

              envelop Contact Supplier

              Bora Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual BoothBora Pharmaceuticals- Making success more certain.
              Contact Supplier Contact Supplier
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan

              Details:

              Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: Kyowa Pharmaceutical Industry

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership August 05, 2021

              Bora Pharmaceutical

              Bio Korea

              Booth #A4

              envelop Contact Supplier

              Bora Pharmaceuticals
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY